The complaint filed against the company alleges that management provided false and misleading market updates concerning CVS Caremark formulary and coverage approval decisions. According to the litigation, ARS Pharmaceuticals was aware that its projected timeline faced significant hurdles, yet it failed to disclose these setbacks to shareholders. This omission allegedly painted a distorted picture of the company's operational viability during the class period.

The DJS Law Group is currently organizing the litigation, inviting affected investors to come forward before the October 5, 2026, deadline. While the firm emphasizes its background in aggressive advocacy for hedge funds and institutional investors, the current action seeks to provide a path for individual shareholders to recover losses sustained due to the stock's performance. Participation as a lead plaintiff is optional, and the firm notes that the suit focuses on potential breaches of sections 10(b) and 20(a) of the Securities Exchange Act.